Clinical bottom line
Minimal residual disease (MRD) detection and eradication have become pivotal in managing acute lymphoblastic leukemia (ALL), offering a sensitive biomarker to guide risk-adapted therapy and improve outcomes. Recent advancements in novel agents targeting MRD-positive ALL, including immunotherapies such as bispecific T-cell engagers and antibody-drug conjugates, show promise in reducing relapse risk by eliminating residual leukemic cells undetectable by conventional methods. While these therapies are increasingly integrated into treatment algorithms, their optimal timing, patient selection, and long-term benefits require further validation. Clinicians should consider MRD status as a dynamic biomarker to tailor therapy intensity and incorporate emerging agents judiciously within multidisciplinary care.
What the evidence shows
MRD assessment using highly sensitive techniques such as flow cytometry and polymerase chain reaction (PCR) has transformed ALL management by identifying patients at high relapse risk despite morphological remission (Della Starza et al., 2019; Bassan et al., 2015). MRD positivity after induction or consolidation therapy correlates strongly with inferior survival, prompting intensified or alternative treatment approaches (Paul et al., 2016).
Recent therapeutic advances focus on novel agents that specifically target MRD-positive leukemic cells. Immunotherapies such as blinatumomab, a bispecific CD19/CD3 T-cell engager, have demonstrated efficacy in eradicating MRD and improving event-free survival in both pediatric and adult ALL (Inaba et al., 2019). Similarly, antibody-drug conjugates like inotuzumab ozogamicin target CD22-positive residual blasts, offering another mechanism to clear MRD (Inaba et al., 2019).
These agents have been studied primarily in relapsed/refractory settings but are increasingly evaluated as consolidation or maintenance therapies to prevent relapse in MRD-positive patients (Della Starza et al., 2019). The integration of MRD-guided immunotherapy allows for more personalized treatment, potentially reducing the need for intensive chemotherapy or allogeneic stem cell transplantation in select cases (Bassan et al., 2015).
Caveats and uncertainty
Despite promising results, several uncertainties remain. The heterogeneity of MRD detection methods and thresholds complicates standardization across centers, potentially affecting treatment decisions (Della Starza et al., 2019). While flow cytometry and PCR remain the mainstays, differences in sensitivity and specificity require careful interpretation (Neale et al., 2003; Campana et al., 2003).
Long-term safety and efficacy data for novel MRD-targeting agents in frontline settings are limited, and their optimal sequencing with conventional chemotherapy or transplantation is not fully established (Inaba et al., 2019). Resistance mechanisms to immunotherapies, such as antigen loss or T-cell exhaustion, also pose challenges (Inaba et al., 2019).
Furthermore, the cost and accessibility of these novel agents and MRD testing platforms may limit widespread implementation, especially in resource-constrained settings. Clinical trials with larger cohorts and longer follow-up are needed to define which patients derive the greatest benefit and to optimize treatment algorithms (Bassan et al., 2015).
How this may change practice
Incorporating MRD assessment as a routine biomarker enables clinicians to stratify ALL patients more precisely and tailor therapy intensity accordingly. The availability of novel agents targeting MRD-positive disease offers opportunities to improve remission durability and reduce relapse rates, particularly in high-risk or relapsed patients.
Practitioners should consider integrating MRD-guided immunotherapies such as blinatumomab or inotuzumab ozogamicin into treatment plans for patients with persistent MRD after induction or consolidation. This approach may allow de-escalation of cytotoxic chemotherapy or avoidance of allogeneic transplantation in some cases, potentially reducing treatment-related morbidity.
Ongoing clinical trials and real-world data will clarify the role of these agents in frontline and maintenance settings. Hematologists should remain current with evolving MRD detection technologies and emerging therapeutic options to optimize individualized care pathways for ALL patients.